Moderna posts surprise profit
Moderna Delivers Surprise Q3 Profit as Cost-Cutting and Strong COVID Vaccine Sales Drive Growth
Moderna surprised Wall Street with a third-quarter profit on Thursday, driven by robust COVID-19 vaccine sales and significant cost-cutting measures. The Cambridge, Massachusetts-based biotech company posted net income of $13 million,
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...
Bank of America Securities analyst Alec Stranahan reiterated a Hold rating on Moderna (MRNA – Research Report) today and set a price ...
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
With flu season underway and new, developing COVID-19 strains, health professionals continue to stress the importance of receiving an updated vaccine. On Oct. 23, the Centers for Disease Control ...
Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product sales of $2.2 ...
Moderna earned $5.4 billion in U.S. revenues in 2021 and $4.4 billion in 2022 from COVID-19 vaccine sales. Northwestern University’s nanotechnology research institute, IIN, has supported over $2 ...
2 strain, prompting the approval of updated versions of the Pfizer and Moderna vaccines targeting that particular strain, and the Novavax vaccine, targeting its parent strain, JN.1, for the 2024 ...
Studies have shown these vaccines to be effective, with the Pfizer, GSK, and Moderna vaccines preventing RSV pneumonia and bronchitis in more than 80 percent of participants. A recent study ...
Moderna, Inc. (NASDAQ:MRNA) is a pharmaceutical and biotechnology company specializing in RNA therapeutics, particularly mRNA vaccines. The company gained widespread recognition for its COVID-19 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback